Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31330695 | 0.89 | DDB1 (0.59) | DDB1CRBNCHEK2ALOX5APFEN1 | |
| SCHEMBL30705914 | 0.86 | DDB1 (0.70) | DDB1CRBNBACE1CTSD | |
| SCHEMBL30706148 | 0.86 | DDB1 (0.70) | DDB1CRBNBACE1CTSD | |
| SCHEMBL30706026 | 0.85 | DDB1 (0.69) | DDB1CRBN | |
| SCHEMBL30735448 | 0.85 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL26636270 | 0.85 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL30705957 | 0.85 | DDB1 (0.68) | DDB1CRBN | |
| SCHEMBL30706020 | 0.85 | DDB1 (0.68) | DDB1CRBNBACE1CTSD | |
| SCHEMBL30257614 | 0.85 | DDB1 (0.70) | DDB1CRBN | |
| SCHEMBL30662917 | 0.84 | DDB1 (0.67) | DDB1CRBNSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | DDB1 141/4885CRBN 756/4885CHEK2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.